Professor Chunyi Hao: advances in the treatment of locally advanced pancreatic cancer

Pancreatic cancer is one of malignancies with a very high mortality due to limited treatments available. Most patients are diagnosed in their advanced stages, and the incidence and mortality remained almost the same for this so-called “the king of cancers”. In the Early of this year, albumin-bound paclitaxel became a prospective regimen for patients with advanced pancreatic cancer and was proposed by the MPACT study published over the annual American Society of Clinical Oncology, Gastrointestinal Cancer Forum (ASCO GI) meeting in San Francisco. DXY interviewed with Professor Hao CY from Beijing Cancer Hospital on the treatments of locally advanced pancreatic cancer over the Expert Seminar on pancreatic cancer treatment progress sponsored by the Chinese Anti-Cancer Association.